Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Intravesical
100%
Mitomycin C
100%
T1 Bladder Cancer
100%
Bacillus Calmette
100%
Meta-analysis
33%
Tumor Recurrence
27%
Disease Progression
22%
Log Hazard Ratio
22%
High Risk
11%
No Significant Difference
11%
Disease Survival
11%
Recurrence Risk
5%
Clinical High Risk
5%
Subgroup Analysis
5%
Transurethral Resection
5%
Data Extraction
5%
Recurrent Disease
5%
Overall Survival
5%
Intravesical Administration
5%
Adverse Events
5%
Fever
5%
Two-agent
5%
Sensitivity Analysis
5%
Treatment Toxicity
5%
MEDLINE
5%
Cochrane
5%
Embase
5%
Search Methods
5%
Systemic Side Effects
5%
Weighted Mean
5%
Hematuria
5%
Systemic Toxicity
5%
Malaise
5%
Selection Criteria
5%
Comprehensive Search
5%
Methodological Quality
5%
Dysuria
5%
Clinical Problems
5%
Skin Rash
5%
Cystitis
5%
Prophylactic Activity
5%
Trial Eligibility
5%
Time-to-event Analysis
5%
Local Toxicity
5%
Recurrent Rate
5%
Local Side Effects
5%
Patient Risk
5%
Decision to Use
5%
Medicine and Dentistry
Bladder Cancer
100%
Mitomycin
100%
Meta-Analysis
37%
Tumor Recurrence
31%
Disease Exacerbation
25%
Hazard Ratio
25%
Arm
18%
Systematic Review
12%
Recurrent Disease
12%
Health Care Cost
6%
Low Drug Dose
6%
Subgroup Analysis
6%
Adverse Event
6%
Exanthem
6%
Overall Survival
6%
Transurethral Resection
6%
Microhematuria
6%
Malaise
6%
Strangury
6%
Cystitis
6%
Intravesical Drug Administration
6%
Chill
6%
Side Effect
6%
Nursing and Health Professions
Bladder Cancer
100%
Mitomycin
100%
Meta Analysis
37%
Tumor Recurrence
31%
Hazard Ratio
25%
Disease Exacerbation
25%
Systematic Review
12%
Recurrent Disease
12%
Rash
6%
Cochrane Library
6%
Medline
6%
Dysuria
6%
Low Drug Dose
6%
Adverse Event
6%
Overall Survival
6%
Data Extraction
6%
Transurethral Resection
6%
Chill
6%
Cystitis
6%
Intravesical Drug Administration
6%
Malaise
6%
Efficacy
6%
Side Effect
6%
Pharmacology, Toxicology and Pharmaceutical Science
Mitomycin
100%
Bladder Cancer
100%
Bacilli
100%
Tumor Recurrence
31%
Disease Exacerbation
25%
Recurrent Disease
12%
Adverse Event
6%
Overall Survival
6%
Rash
6%
Malaise
6%
Cystitis
6%
Strangury
6%
Chill
6%
Side Effect
6%
Immunology and Microbiology
Arm
100%
Low Drug Dose
33%
Overall Survival
33%
Medline
33%
Cochrane Library
33%
Data Extraction
33%